The role of azacitidine in the management of myelodysplastic syndromes (MDS)

References

• WilliamsonPJKrugerARReynoldsPJHamblinTJOscierDGEstablishing the incidence of myelodysplastic syndromeBr J Haematol1994877437457986716
   PubMed Web of Science ®Google Scholar
• GermingUAulCNiemeyerCMHaasRBennettJMEpidemiology, classification and prognosis of adults and children with myelodysplastic syndromesAnn Hematol20088769169918575866
   PubMed Web of Science ®Google Scholar
• RollisonDEHowladerNSmithMTEpidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programsBlood2008112455218443215
   PubMed Web of Science ®Google Scholar
• GreenbergPCoxCLeBeauMMInternational scoring system for evaluating prognosis in myelodysplastic syndromesBlood199789207920889058730
   PubMed Web of Science ®Google Scholar
• GermingUHildebrandtBPfeilstockerMRefinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)Leukemia2005192223223116193087
   PubMed Web of Science ®Google Scholar
• MalcovatiLGermingUKuendgenATime-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromesJ Clin Oncol2007253503351017687155
   PubMed Web of Science ®Google Scholar
• ParkMJKimHJKimSHIs International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSSEur J Haematol20088136437318637029
   PubMed Web of Science ®Google Scholar
• Hellström-LindbergENegrinRSteinRErythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive modelBr J Haematol1997993443519375752
   PubMed Web of Science ®Google Scholar
• JäderstenMMontgomerySMDybedalIPorwit-MacDonaldAHellström-LindbergELong-term outcome of treatment of anemia in MDS with erythropoietin and G-CSFBlood200510680381115840690
   PubMed Web of Science ®Google Scholar
• ListAKurtinSRoeDJEfficacy of lenalidomide in myelodysplastic syndromesN Engl J Med200535254955715703420
   PubMed Web of Science ®Google Scholar
• ListADewaldGBennettJLenalidomide in the myelodysplastic syndrome with chromosome 5q deletionN Engl J Med20063551456146517021321
   PubMed Web of Science ®Google Scholar
• RazaAReevesJAFeldmanEJPhase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qBlood2008111869317893227
   PubMed Web of Science ®Google Scholar
• LimZYKillickSGermingULow IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulinLeukemia2007211436144117507999
   PubMed Web of Science ®Google Scholar
• SaunthararajahYNakamuraRWesleyRWangQJBarrettAJA simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndromeBlood20031023025302712829603
   PubMed Web of Science ®Google Scholar
• ParkSGrabarSKelaidiCPredictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experienceBlood200811157458217940203
   PubMed Web of Science ®Google Scholar
• JäderstenMMalcovatiLDybedalIErythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndromeJ Clin Oncol2008263607361318559873
   PubMed Web of Science ®Google Scholar
• de WitteTSuciuSVerhoefGIntensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDSBlood2001982326233111588026
   PubMed Web of Science ®Google Scholar
• KrogerNBornhauserMEhningerGAllogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemiaAnn Hematol20038233634212728337
   PubMed Web of Science ®Google Scholar
• HoAYPagliucaAKenyonMReduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioningBlood20041041616162315059843
   PubMed Web of Science ®Google Scholar
• NachtkampKKundgenAStruppCImpact on survival of different treatments for myelodysplastic syndromes (MDS)Leuk Res2009331024102819185917
   PubMed Web of Science ®Google Scholar
• AppelbaumFRAndersonJAllogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS scoreLeukemia199812Suppl 1S25S299777891
   PubMed Web of Science ®Google Scholar
• PlatzbeckerUBornhauserMGermingURed blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS)Biol Blood Marrow Transplant2008141217122518940675
   PubMed Web of Science ®Google Scholar
• SorrorMLSandmaierBMStorerBEComorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantationJ Clin Oncol2007254246425417724349
   PubMed Web of Science ®Google Scholar
• HallemeierCLGirgisMDBlumWGLong-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamideBiol Blood Marrow Transplant20061274975716785064
   PubMed Web of Science ®Google Scholar
• de LimaMAnagnostopoulosAMunsellMNonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantationBlood200410486587215090449
   PubMed Web of Science ®Google Scholar
• DeegHJGuardiolaPAllogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosisInt J Hematol200276Suppl 2293412430896
   PubMed Web of Science ®Google Scholar
• WallenHGooleyTADeegHJAblative allogeneic hematopoietic cell transplantation in adults 60 years of age and olderJ Clin Oncol2005233439344615824415
   PubMed Web of Science ®Google Scholar
• EstellerMProfiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the icebergClin Immunol2003109808814585279
   PubMed Web of Science ®Google Scholar
• JonesPABaylinSBThe fundamental role of epigenetic events in cancerNat Rev Genet2002341542812042769
   PubMed Web of Science ®Google Scholar
• RobertsonKDDNA methylation and human diseaseNat Rev Genet2005659761016136652
   PubMed Web of Science ®Google Scholar
• AokiEUchidaTOhashiHMethylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromesLeukemia20001458659310764143
   PubMed Web of Science ®Google Scholar
• AggerholmAHolmMSGuldbergPOlesenLHHoklandPPromoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patientsEur J Haematol200676233216343268
   PubMed Web of Science ®Google Scholar
• ChristiansenDHAndersenMKPedersen-BjergaardJMethylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemiaLeukemia2003171813181912970781
   PubMed Web of Science ®Google Scholar
• QuesnelBGuillermGVereecqueRMethylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progressionBlood199891298529909531610
   PubMed Web of Science ®Google Scholar
• TienHFTangJHTsayWMethylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformationBr J Haematol200111214815411167795
   PubMed Web of Science ®Google Scholar
• GrovdalMKhanRAggerholmANegative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndromeClin Cancer Res2007137107711218056190
   PubMed Web of Science ®Google Scholar
• JonesPATaylorSMWilsonVLInhibition of DNA methylation by 5-azacytidineRecent Results Cancer Res1983842022116189159
   PubMedGoogle Scholar
• DaskalakisMNguyenTTNguyenCDemethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2’-deoxycytidine (decitabine) treatmentBlood20021002957296412351408
   PubMed Web of Science ®Google Scholar
• RajKJohnAHoACDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidineLeukemia2007211937194417611569
   PubMed Web of Science ®Google Scholar
• KaminskasEFarrellAAbrahamSApproval summary: azacitidine for treatment of myelodysplastic syndrome subtypesClin Cancer Res2005113604360815897554
   PubMed Web of Science ®Google Scholar
• GloverABLeyland-JonesBBiochemistry of azacitidine: a reviewCancer Treat Rep1987719599642443243
   PubMedGoogle Scholar
• MomparlerRLPharmacology of 5-Aza-2’-deoxycytidine (decitabine)Semin Hematol200542S9S1616015507
   PubMed Web of Science ®Google Scholar
• JabbourEIssaJPGarcia-ManeroGKantorjianHEvolution of decitabine developmentCancer20081122341235118398832
   PubMed Web of Science ®Google Scholar
• KaminskasEFarrellATWangYCSridharaRPazdurRFDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspensionOncologist20051017618215793220
   PubMed Web of Science ®Google Scholar
• ChabotGGRivardGEMomparlerRLPlasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2’-deoxycytidine in rabbits and dogsCancer Res1983435925976184151
   PubMed Web of Science ®Google Scholar
• SilvermanLRDemakosEPPetersonBLRandomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group BJ Clin Oncol2002202429244012011120
   PubMed Web of Science ®Google Scholar
• SilvermanLRMcKenzieDRPetersonBLFurther analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group BJ Clin Oncol2006243895390316921040
   PubMed Web of Science ®Google Scholar
• FenauxPMuftiGJHellstrom-LindbergEEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol20091022323219230772
   PubMed Web of Science ®Google Scholar
• ChesonBDBennettJMKantarjianHReport of an international working group to standardize response criteria for myelodysplastic syndromesBlood2000963671367411090046
   PubMed Web of Science ®Google Scholar
• ChesonBDGreenbergPLBennettJMClinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood200610841942516609072
   PubMed Web of Science ®Google Scholar
• WijermansPWKrulderJWHuijgensPCNevePContinuous infusion of low-dose 5-Aza-2’-deoxycytidine in elderly patients with high-risk myelodysplastic syndromeLeukemia199711159001409
   PubMed Web of Science ®Google Scholar
• WijermansPLubbertMVerhoefGLow-dose 5-Aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patientsJ Clin Oncol20001895696210694544
   PubMed Web of Science ®Google Scholar
• KantarjianHIssaJPRosenfeldCSDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer20061061794180316532500
   PubMed Web of Science ®Google Scholar
• SteensmaDPBaerMRSlackJLMulticenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialJ Clin Oncol2009273842384819528372
   PubMed Web of Science ®Google Scholar
• WijermansPSSBailaLPlatzbeckerULow dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible forintensive chemotherapy: Final results of the randomized phase III study (06011) of the EORTC leukemia and German MDS study groupsBlood2008112 Abstr 226.
   Web of Science ®Google Scholar
• LemaireMChabotGGRaynalNJImportance of dose-schedule of 5-aza-2’-deoxycytidine for epigenetic therapy of cancerBMC Cancer2008812818454857
   PubMed Web of Science ®Google Scholar
• HaaseDGermingUSchanzJNew insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patientsBlood20071104385439517726160
   PubMed Web of Science ®Google Scholar
• KnippSHildebrandBKundgenAIntensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypesCancer200711034535217559141
   PubMed Web of Science ®Google Scholar
• MuftiGJGarcia-ManeroGHovarthNLimZProlonged survival in higher-risk myelodysplastic syndrome (MDS) patients with −7/Del(7q) treated with azacitidine (AZA)Haematologica200893 Abstr 0928.
   Web of Science ®Google Scholar
• MuftiGJFenauxPHellström-LindbergESantiniVTreatment of high-risk MDS patients (pts) with −7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS)J Clin Oncol200826 Abstr 7033.
   Web of Science ®Google Scholar
• RuterBWijermansPClausRKunzmannRLubbertMPreferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7Blood200711010801082 Author reply 1083.17644749
   PubMed Web of Science ®Google Scholar
• SeymourJFFenauxPSilvermanLBEffects of azacitidine (AZA) vs conventional care regimens (CCR) in elderly (>=75 years) patients (pts) with myelodysplastic syndromes (MDS) from the AZA-001 survival trialBlood20081123629a
   Web of Science ®Google Scholar
• LyonsRMCosgriffTMModiSSHematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromesJ Clin Oncol2009271850185619255328
   PubMed Web of Science ®Google Scholar
• RobertsonKDDNA methylation, methyltransferases, and cancerOncogene2001203139315511420731
   PubMed Web of Science ®Google Scholar
• ChristmanJK5-Azacytidine and 5-aza-2’-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapyOncogene2002215483549512154409
   PubMed Web of Science ®Google Scholar
• StresemannCLykoFModes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInt J Cancer200812381318425818
   PubMed Web of Science ®Google Scholar
• SilvermanLRFenauxPMuftiGJThe effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients (pts) with myelodysplastic syndromes (MDS)Blood2008112227a
   Web of Science ®Google Scholar
• Müller-ThomasCSchusterTPeschelCGötzeKSA limited number of 5-azacitidine cycles can be effective treatment in MDSAnn Hematol20098821321918696067
   PubMed Web of Science ®Google Scholar
• ListAFFenauxPMuftiGJHellström-LindbergEEffect of azacitidine (AZA) on overall suvival in higher-risk myelodysplastic syndromes (MDS) without complete remissionJ Clin Oncol200826 Abstr 7006.
   Web of Science ®Google Scholar
• RajKMuftiGJAzacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromesTher Clin Risk Manag2006237738818360650
   PubMedGoogle Scholar
• KornblithABHerndonJE2ndSilvermanLRImpact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B studyJ Clin Oncol2002202441245212011121
   PubMed Web of Science ®Google Scholar
• SantiniVFPMuftiGJHellström-LindbergEPatient outcome during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)J Clin Oncol200826 Abstr 7028.
   Web of Science ®Google Scholar